NCT03080974 is a Phase 2 clinical trial of Nivolumab in Pancreatic Adenocarcinoma, sponsored by University of Louisville.

Who is sponsoring NCT03080974?

NCT03080974 is sponsored by University of Louisville.

What drugs are being tested in NCT03080974?

Interventions in NCT03080974: Nivolumab, Irreversible Electroporation.

What condition does NCT03080974 study?

NCT03080974 studies Pancreatic Adenocarcinoma.

Is NCT03080974 still recruiting?

NCT03080974 is currently recruiting now. Last updated 29 October 2025.

Last reviewed 2025-10-29 · How we verify

NCT03080974

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting now Phase 2 Last updated 29 October 2025

What this trial tests

Phase 2 trial testing Nivolumab in Pancreatic Adenocarcinoma in 10 participants. Currently enrolling.

Timeline

14 August 2017

Primary endpoint
1 June 2028

1 April 2029

Quick facts

Lead sponsor	University of Louisville
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	14 August 2017
Primary completion	1 June 2028
Estimated completion	1 April 2029
Sites	1 location across United States

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →
Irreversible Electroporation

Conditions studied

Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →

Sponsor

University of Louisville

Who can join

18 and older, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.
Burbach BJ, O'Flanagan SD, Shao Q, Young KM, et al · · 2021 · cited 60× · PMID 34162858 · DOI 10.1038/s41467-021-24132-6
A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
O'Neill C, Hayat T, Hamm J, Healey M, et al · · 2020 · cited 49× · PMID 32631655 · DOI 10.1016/j.surg.2020.04.057
Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies.
Bazeed AY, Day CM, Garg S. · · 2022 · cited 42× · PMID 36077794 · DOI 10.3390/cancers14174257
Electroporation and Immunotherapy-Unleashing the Abscopal Effect.
Justesen TF, Orhan A, Raskov H, Nolsoe C, et al · · 2022 · cited 38× · PMID 35740542 · DOI 10.3390/cancers14122876
Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model.
Shankara Narayanan JS, Hayashi T, Erdem S, McArdle S, et al · · 2023 · cited 31× · PMID 36634919 · DOI 10.1136/jitc-2022-006133
Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer.
Lafranceschina S, Brunetti O, Delvecchio A, Conticchio M, et al · · 2019 · cited 29× · PMID 31684186 · DOI 10.3390/cancers11111718
Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.
Pihlak R, Weaver JMJ, Valle JW, McNamara MG. · · 2018 · cited 24× · PMID 29329208 · DOI 10.3390/cancers10010017
Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.
Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, et al · · 2021 · cited 22× · PMID 34790007 · DOI 10.3748/wjg.v27.i40.6775

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Pancreatic Adenocarcinoma

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE · Phase 1 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other University of Louisville trials

Trials by the same sponsor.

NCT07219888 — Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty · Phase 4 · not yet recruiting
NCT07044726 — Betadine vs Sterile Water for Periurethral Preparation · Phase 4 · not yet recruiting
NCT06489106 — Noninvasive Spinal Stimulation to Restore Hand Function in Children With Spinal Cord Injury · NA · enrolling by invitation
NCT06883513 — Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID · NA · recruiting
NCT05920720 — Self-Guided Personalized Treatment for Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03080974 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Louisville
Last refreshed: 29 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03080974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing